Precision Medicine and Artificial Intelligence
The Perfect Fit for Autoimmunity
- 1st Edition - March 12, 2021
- Imprint: Academic Press
- Editor: Michael Mahler
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 2 0 2 3 9 - 5
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 5 4 3 2 - 0
Precision Medicine and Artificial Intelligence: The Perfect Fit for Autoimmunity covers background on artificial intelligence (AI), its link to precision medicine (PM), and examp… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quotePrecision Medicine and Artificial Intelligence: The Perfect Fit for Autoimmunity covers background on artificial intelligence (AI), its link to precision medicine (PM), and examples of AI in healthcare, especially autoimmunity. The book highlights future perspectives and potential directions as AI has gained significant attention during the past decade. Autoimmune diseases are complex and heterogeneous conditions, but exciting new developments and implementation tactics surrounding automated systems have enabled the generation of large datasets, making autoimmunity an ideal target for AI and precision medicine.
More and more diagnostic products utilize AI, which is also starting to be supported by regulatory agencies such as the Food and Drug Administration (FDA). Knowledge generation by leveraging large datasets including demographic, environmental, clinical and biomarker data has the potential to not only impact the diagnosis of patients, but also disease prediction, prognosis and treatment options.
- Allows the readers to gain an overview on precision medicine for autoimmune diseases leveraging AI solutions
- Provides background, milestone and examples of precision medicine
- Outlines the paradigm shift towards precision medicine driven by value-based systems
- Discusses future applications of precision medicine research using AI
- Other aspects covered in the book include regulatory insights, data analytics and visualization, types of biomarkers as well as the role of the patient in precision medicine
This book targets the scientific community at the interface between medicine, biotechnology as well as computer science (i.e., artificial intelligence). From the readers profile perspective, the book is geared towards scientist in academia and in the biotech as well as in the pharmaceutical industry (translational research and biomarker discovery groups / small molecules / drug target discovery). Some of the higher-level chapters of the book provide valuable information for functional heads in the industry (e.g., C-suite, executive level, business development).
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Chapter 1: History, current status, and future directions of artificial intelligence
- Abstract
- Competing interests
- 1: Introduction: History of artificial intelligence
- 2: Enabling technologies
- 3: Introduction of artificial intelligence in life science and healthcare
- 4: Future artificial intelligence development
- Chapter 2: Precision medicine as an approach to autoimmune diseases
- Abstract
- Competing interests
- 1: Introduction
- 2: From individualized to precision medicine
- 3: Trends that promote precision medicine
- 4: Challenges for therapeutics, medical interventions and clinical trials
- 5: Prevention of disease morbidity and mortality
- 6: Mobile devices and web-based software applications and the future of medicine
- 7: Importance of biomarkers
- 8: Health economics
- 9: Conclusion
- Chapter 3: Biomarker and data science as integral part of precision medicine
- Abstract
- 1: Introduction
- 2: Definitions of biomarkers
- 3: Pre-analytical aspects of biomarkers
- 4: Benefits and pitfalls of biomarkers
- 5: Biomarker discovery
- 6: Biomarker verification and validation
- 7: Statistical approaches and big data
- 8: From bench to bedside
- 9: Conclusions
- Chapter 4: Companion and complementary diagnostics: A key to precision medicine
- Abstract
- 1: Introduction
- 2: Companion and complementary diagnostics
- 3: Drug-diagnostic codevelopment
- 4: Regulatory requirements
- 5: Concluding remark
- Chapter 5: Checkpoint inhibitors: Interface of cancer and autoimmunity: Opportunity for second level precision medicine
- Abstract
- Acknowledgments
- Competing interests
- 1: Introduction
- 2: History of immune checkpoint inhibitors
- 3: Mechanisms of immune checkpoint inhibitors
- 4: The interface between cancer and autoimmunity
- 5: Immune-related adverse events
- 6: Patients with pre-existing autoimmunity
- 7: Opportunities for precision medicine
- 8: Management of immune-related adverse events
- 9: Autoantibodies and immune-related adverse events
- 10: Conclusions
- Chapter 6: The evolving potential of precision medicine in the management of autoimmune liver disease
- Abstract
- 1: Introduction
- 2: History of autoimmune liver disease
- 3: Spectrum of autoimmune liver disease
- 4: Laboratory biomarkers of autoimmune liver disease
- 5: Challenges in differential diagnosis of autoimmune liver disease
- 6: Development of precision medicine in autoimmune liver disease
- 7: Conclusions
- Chapter 7: Precision medicine in autoimmune disease
- Abstract
- 1: Introduction
- 2: Precision medicine in the diagnosis and prognosis of autoimmune disease
- 3: Precision medicine and the identification of co-morbidities in autoimmune disease
- 4: Precision medicine in the treatment of autoimmune diseases
- 5: Precision medicine in the evaluation of outcomes in autoimmune disease
- 6: Precision medicine and prediction and prevention of autoimmune disease
- 7: Autoantibodies and other factors are highly predictive of future rheumatoid arthritis (and other autoimmune diseases)
- 8: Identification of meaningful biologic targets for prevention
- 9: “Personalized medicine”—What should (and will) a person do to treat a current autoimmune disease, or prevent a future autoimmune disease?
- 10: Conclusions
- Disclosures
- Chapter 8: Development of multi-omics approach in autoimmune diseases
- Abstract
- Competing interests
- 1: Introduction
- 2: Translation of multi-omics into clinical application
- 3: Types of omics technologies
- 4: Progress and success in autoimmunity
- Chapter 9: N-of-1 trials: Implications for clinical practice and personalized clinical trials
- Abstract
- 1: Introduction
- 2: Lessons learned from case reports and case series
- 3: Complementary medicine approach
- 4: Study designs
- 5: Statistical considerations
- 6: Ethics and insurance
- 7: Regulatory aspects
- 8: Conclusions
- Chapter 10: Health risk assessment and family history: Toward disease prevention
- Abstract
- Financial support and sponsorship
- Conflict of interest
- 1: Background
- 2: Family history as a construct for prevention
- 3: Prevention strategies
- 4: PRE-RA family study
- 5: Pharmacologic prevention
- 6: Conclusions
- Chapter 11: Regulatory aspects of artificial intelligence and machine learning-enabled software as medical devices (SaMD)
- Abstract
- 1: Introduction
- 2: The Food and Drug Administration (FDA)’s perspective
- 3: CE mark and in-vitro diagnostic regulation
- 4: National Medical Products Administration—China
- 5: Data privacy considerations around AI/ML-enabled software
- 6: Challenges to the manufacturers when AI/ML SaMD evolve
- 7: Summary
- Chapter 12: Precision medicine from the patient's perspective: More opportunities and increasing responsibilities
- Abstract
- 1: Introduction
- 2: Challenges of autoimmunity
- 3: Technology and telemedicine
- 4: Direct to consumer information and marketing
- 5: The role of the general practitioner/primary care
- 6: Education and communication
- 7: Patient consulting organizations
- Index
- Edition: 1
- Published: March 12, 2021
- Imprint: Academic Press
- No. of pages: 300
- Language: English
- Paperback ISBN: 9780128202395
- eBook ISBN: 9780323854320
MM
Michael Mahler
Michael Mahler received his Ph.D. from the institute of molecular genetics at the University of Heidelberg (Germany). During his Ph.D. thesis, Michael Mahler worked at The Scripps Research Institute in the laboratory of Prof. Mike Pollard and Prof. Eng Tan. He is currently Vice President of Research at Inova Diagnostics. His research is focused on the B-cell autoimmune response in autoimmune diseases and the discovery of novel autoantigens which resulted in more than 300 peer reviewed journal articles as well as several patents. In addition, he works on the development and characterization of novel diagnostic assays for the diagnosis of autoimmune diseases. In the scientific community, he serves as Editor of different scientific journals and as reviewer for more than 40 journals. Michael Mahler became exposed to and interested in Artificial Intelligence as well as Precision Medicine and as a consequence, co-founded the Precision Medicine in Autoimmunity (PMA) (www.precisionmedicineautoimmunity.org) conference.
Affiliations and expertise
Inova Diagnostics, San Diego, CA, USARead Precision Medicine and Artificial Intelligence on ScienceDirect